📅 January is #CervicalCancerMonth. HPV vaccines have been shown to prevent infection by the HPV types known to cause most cervical cancers. Learn how research from the NCI Center for Cancer Research in the 1990s led to their development: https://go.nih.gov/QUX8bIq National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP)
NCI Center for Cancer Research
Government Administration
Bethesda, MD 27,368 followers
Creating the cancer medicines of tomorrow through bold biomedical research
About us
CCR is the basic and clinical intramural research program of the National Cancer Institute at the National Institutes of Health working to make breakthrough scientific discoveries to find cures and treatments for cancer. Our scientists work on a wide spectrum of biological and biomedical problems that range from visualizing and understanding the structure of individual genes and proteins and developing novel methods for drug discovery to inventing biomedical devices and technology and creating innovative ways to treat patients on clinical trials that take place in the NIH Clinical Center in Bethesda, Maryland. During the past two decades, work in CCR has led to numerous landmark scientific discoveries and made a positive public health impact, including the development of groundbreaking immunotherapy approaches, HIV/AIDS testing, the creation of a HPV vaccine and more. Our Principal Investigators lead teams of laboratory scientists, trainees, clinicians, patient-care providers and administrators to unlock scientific knowledge to advance the fight against cancer and HIV/AIDS. We are dedicated to reaching our vision of a fully inclusive workplace in CCR. At CCR, we do cancer research that benefits all. More information on career opportunities: https://ccr.cancer.gov/careers NCI Privacy Policy: https://www.cancer.gov/policies/privacy-security Engagement ≠ endorsement.
- Website
-
https://ccr.cancer.gov/
External link for NCI Center for Cancer Research
- Industry
- Government Administration
- Company size
- 1,001-5,000 employees
- Headquarters
- Bethesda, MD
- Specialties
- cancer, cancer research , fellowship training, cancer careers, and clinical trials
Updates
-
CCR is honored to be included in Dr. Monica Bertagnolli's 2024 science highlights! Dr. Eytan Ruppin, Chief of our Cancer Data Science Laboratory, published research this year on an AI tool that uses single-cell analysis to match drugs to cancer patients. Read more in the NIH Director's Blog ⤵️
This year on my blog, we covered a wide range of NIH-supported research and explored exciting new findings. Highlights included learning more about the human brain, use of AI technology in health, discovering clues about chronic autoimmune conditions, understanding the underlying reasons why people develop Long COVID, and more! Read all about the 2024 highlights in this week’s blog post. #ScienceHighlights #science #research #ScienceDiscoveries #NewScience #NIH
-
2024 was a big year in #CancerResearch! Check out Dr. Kimryn Rathmell's list of noteworthy advances and see if you can spot the research done here in CCR. ⤵️
What a year it’s been for cancer research! NCI Director Dr. Kimryn Rathmell shares 24 noteworthy advances from 2024 that are shaping the future of cancer care. Which ones stand out to you? #2024recap #CancerResearch
The year in cancer: 24 advances in 2024
National Cancer Institute (NCI) on LinkedIn
-
⭐ CCR Year-end Roundup: Our Most Viewed Science Stories of 2024 The last science story in our roundup comes from the lab of Dr. Louis Staudt! Polatuzumab vedotin (Polivy), or "Pola-V” is the first new drug approved for diffuse large B-cell lymphoma (#DLBCL) treatment in 20 years. Dr. Staudt and his team’s recent research provides a new method that can help improve patient responses and decrease side effects to the drug. Read more about the new technique below ⤵️
💡 NEW FINDINGS: Researchers uncovered the mechanisms behind a drug treatment for diffuse large B-cell lymphoma (DLBCL). The findings help clarify why certain patients respond well to the treatment, while others do not. ➡ Read more: https://lnkd.in/esHMrS8A DLBCL is the most common type of aggressive non-Hodgkin lymphoma. Louis M. Staudt, M.D., Ph.D., Chief of the Lymphoid Malignancies Branch, and his colleagues led this important research. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP), The National Institutes of Health #CancerResearch #Lymphoma #Innovation #Health #Medicine
-
-
⭐ CCR Year-end Roundup: Our Most Viewed Science Stories of 2024 #Sarcomas are a diverse group of rare malignancies comprised of multiple different clinical and molecular subtypes. Outcomes for patients are generally poor due to a lack of novel therapies and an incomplete understanding of the diseases’ biology. The Sarcoma CellMinerCDB, a cross-NIH collaborative project, will help address this limitation: Read more about the database ⤵️
📣 NEW RESOURCE: CCR researchers have developed the largest publicly accessible sarcoma cell line database called Sarcoma CellMinerCDB. The tool merges previously available and new sarcoma cell line data that can be used to identify new therapeutic targets for these cancers. The database will help researchers worldwide address and generate biological questions and test hypotheses for translational research into new therapies and solutions for sarcoma patients. National Cancer Institute (NCI), National Center for Advancing Translational Sciences (NCATS) ➡ Learn more: https://lnkd.in/gdT6ihH9
-
-
⭐ CCR Year-end Roundup: Our Most Viewed Science Stories of 2024 A team of researchers led by Doug Lowy, M.D., Chief of the Laboratory of Cellular Oncology and Principal Deputy Director of the National Cancer Institute, uncovered a surprising discovery about one of the most rigorously studied oncoproteins in human cancer. It may be possible to exploit this previously unrecognized role of RAS to develop combination therapies that boost the anti-cancer effects of RAS-inhibiting drugs. ➡️ Read the NCI press release: https://go.nih.gov/sIo7TT5 and read the CCR news story below ⤵️
💡 NEW FINDINGS: RAS genes are the second most mutated genes in human cancer and the subject of decades of intense study. Now, CCR scientists have discovered that RAS proteins have a previously overlooked role: they can help shuttle other proteins out of a cell’s nucleus and into the cytoplasm. The transport they facilitate creates opportunities for some relocated proteins to support cancerous growth. ➡ Read more: https://go.nih.gov/lIJJFJR Image: CCR researchers showed that RAS can colocalize with RAN-GAP (red dots) at the edge of the cell nucleus (bright blue), where it helps trigger nuclear transport machinery to release cargo proteins such as EZH2 into the cytoplasm. National Cancer Institute (NCI), The National Institutes of Health, National Institutes of Health (NIH): Intramural Research Program (IRP)
-
-
⭐ CCR Year-end Roundup: Our Most Viewed Science Stories of 2024 Dr. Munira Basrai and her team focus on the molecular mechanisms for regular chromosome separation in growing yeast and human cells. Chromosomes are known to play an important role in defining how organisms develop, function and remain healthy: much can go awry if they experience issues during cell division. Read more about one of Dr. Basrai’s findings this year about chromosome stability ⤵️
📣 ONGOING RESEARCH: A new study shines light on a cellular process that can cause chromosome abnormalities, which are linked to many types of cancer. ➡ Learn more: https://go.nih.gov/gGcZ4iL This work was led by Dr. Munira A. Basrai, a senior investigator in our Genetics Branch. Currently, the Basrai group is working to learn more about the consequences of histone H3 mutations on chromosomal instability, as these mutations are found in several cancers. This work may help identify biomarkers that can aid in the prognosis of CENP-A overexpressing cancers. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) #CancerResearch #Genetics #Innovation #NewFindings
-
-
🗞️ IN THE NEWS: Lori Wiener, Ph.D., DCSW, LCSW-C, from our Pediatric Oncology Branch, was quoted in a Cancer Currents article about new studies that have found surveying young patients about their symptoms during cancer treatment can improve care and reduce side effects. 📢 “That’s why this study is so exciting—because they married the [symptom] screening with guidance for providers on how to respond to this information, so that it could truly have an impact in an immediate and very systematic way,” Dr. Wiener said. ➡️ Read the full article: https://go.nih.gov/MPywbjI National Cancer Institute (NCI)
Tool Improves Supportive Care in Young Cancer Patients
cancer.gov
-
⭐ CCR Year-end Roundup: Our Most Viewed Science Stories of 2024 CCR researchers pioneered the study of chromatin (intricately wound strands of DNA wrapped around proteins called histones), demonstrating its functional importance in cancer and other diseases. Uncovering these mechanisms help researchers understand how normal and diseased cells survive or not. Read more about one such DNA discovery led by andre nussenzweig from this year ⤵️
💡 ONGOING RESEARCH: DNA replication can generate potentially catastrophic double-strand DNA breaks. A new study from CCR scientists, led by Andre Nussenzweig, Ph.D., Chief of the Laboratory of Genome Integrity, details how these breaks arise and how cells repair the damage. Understanding the repair of replication-associated double-strand breaks is important for devising better cancer therapies, as many systemic chemotherapies kill cancer cells by triggering these kinds of breaks. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP), andre nussenzweig ➡ Read more: https://lnkd.in/e4xhgeWa #CancerResearch #DNA #CancerGenome #Innovation #Technology
-